NGF and neoplasm: NGF activates the pro-myosin receptor kinase (Trk), and Lar@NP-OMVs (which contain Trk inhibitors) directly disrupt neural activity by inhibiting the neurotrophic factor/Trk signaling pathway and converting M2-type tumor-associated macrophages (TAMs) to M1-type and enhancing the efficacy of gemcitabine (88).